Development of a novel multi-epitope mRNA vaccine candidate to combat HMPV virus

References

• van den Hoogen BG, de Jong JC, Groen J, Kuiken T, de Groot R, Fouchier RA, Osterhaus ADME. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med. 2001;7(6):719–16. doi:10.1038/89098.
   PubMed Web of Science ®Google Scholar
• Perez A, Lively JY, Curns A, Weinberg GA, Halasa NB, Staat MA, Szilagyi PG, Stewart LS, McNeal MM, Clopper B, et al. Respiratory virus surveillance among children with acute respiratory illnesses — new vaccine surveillance network, United States, 2016–2021. MMWR Morb Mortal Wkly Rep. 2022;71(40):1253–9. doi:10.15585/mmwr.mm7140a1.
   PubMed Web of Science ®Google Scholar
• CDC amecira. Human metapneumovirus (HMPV). National Trends. https://www.cdc.gov/surveillance/nrevss/hmpv/natl-trend.html.
   Google Scholar
• Haynes AK, Fowlkes AL, Schneider E, Mutuc JD, Armstrong GL, Gerber SI. Human metapneumovirus circulation in the United States, 2008 to 2014. Pediatrics. 2016;137(5). doi:10.1542/peds.2015-2927.
   PubMed Web of Science ®Google Scholar
• Williams JV, Harris PA, Tollefson SJ, Halburnt-Rush LL, Pingsterhaus JM, Edwards KM, Wright PF, Crowe JE. Human metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children. N Engl J Med. 2004;350(5):443–50. doi:10.1056/NEJMoa025472.
   PubMed Web of Science ®Google Scholar
• Walsh EE, Peterson DR, Falsey AR. Human metapneumovirus infections in adults: another piece of the puzzle. Arch Intern Med. 2008;168(22):2489–96. doi:10.1001/archinte.168.22.2489.
   PubMedGoogle Scholar
• Wang X, Li Y, Deloria-Knoll M, Madhi SA, Cohen C, Ali A, Basnet S, Bassat Q, Brooks WA, Chittaganpitch M, et al. Global burden of acute lower respiratory infection associated with human metapneumovirus in children under 5 years in 2018: a systematic review and modelling study. Lancet Glob Health. 2021;9(1):e33–e43. doi:10.1016/S2214-109X(20)30393-4.
   PubMed Web of Science ®Google Scholar
• Shahda S, Carlos WG, Kiel PJ, Khan BA, Hage CA. The human metapneumovirus: a case series and review of the literature. Transpl Infect Dis. 2011;13(3):324–8. doi:10.1111/j.1399-3062.2010.00575.x.
   PubMed Web of Science ®Google Scholar
• Haas LE, Thijsen SF, van Elden L, Heemstra KA. Human metapneumovirus in adults. Viruses. 2013;5(1):87–110. doi:10.3390/v5010087.
   PubMed Web of Science ®Google Scholar
• Gaunt ER, Jansen RR, Poovorawan Y, Templeton KE, Toms GL, Simmonds P, Fouchier R. Molecular epidemiology and evolution of human respiratory syncytial virus and human metapneumovirus. PLoS One. 2011;6(3):e17427. doi:10.1371/journal.pone.0017427.
   PubMed Web of Science ®Google Scholar
• Biacchesi S, Skiadopoulos MH, Boivin G, Hanson CT, Murphy BR, Collins PL, Buchholz UJ. Genetic diversity between human metapneumovirus subgroups. Virology. 2003;315(1):1–9. doi:10.1016/S0042-6822(03)00528-2.
   PubMed Web of Science ®Google Scholar
• Shafagati N, Williams J. Human metapneumovirus - what we know now. F1000Res. 2018;7:135. doi:10.12688/f1000research.12625.1.
   PubMedGoogle Scholar
• Wilson RL, Fuentes SM, Wang P, Taddeo EC, Klatt A, Henderson AJ, He B. Function of small hydrophobic proteins of paramyxovirus. J Virol. 2006;80(4):1700–9. doi:10.1128/JVI.80.4.1700-1709.2006.
   PubMed Web of Science ®Google Scholar
• Herfst S, Fouchier RA. Vaccination approaches to combat human metapneumovirus lower respiratory tract infections. J Clin Virol. 2008;41(1):49–52. doi:10.1016/j.jcv.2007.10.022.
   PubMed Web of Science ®Google Scholar
• Herfst S, Schrauwen EJ, de Graaf M, van Amerongen G, van den Hoogen BG, de Swart RL, Osterhaus ADME, Fouchier RAM. Immunogenicity and efficacy of two candidate human metapneumovirus vaccines in cynomolgus macaques. Vaccine. 2008;26(33):4224–30. doi:10.1016/j.vaccine.2008.05.052.
   PubMed Web of Science ®Google Scholar
• Olmedillas E, Cano O, Martinez I, Luque D, Terron MC, McLellan JS, Melero JA, Más V. Chimeric Pneumoviridae fusion proteins as immunogens to induce cross-neutralizing antibody responses. EMBO Mol Med. 2018;10(2):175–87. doi:10.15252/emmm.201708078.
   PubMed Web of Science ®Google Scholar
• Herd KA, Mahalingam S, Mackay IM, Nissen M, Sloots TP, Tindle RW. Cytotoxic T-lymphocyte epitope vaccination protects against human metapneumovirus infection and disease in mice. J Virol. 2006;80(4):2034–44. doi:10.1128/JVI.80.4.2034-2044.2006.
   PubMed Web of Science ®Google Scholar
• Melendi GA, Zavala F, Buchholz UJ, Boivin G, Collins PL, Kleeberger SR, Polack FP. Mapping and characterization of the primary and anamnestic H-2 d -restricted cytotoxic T-lymphocyte response in mice against human metapneumovirus. J Virol. 2007;81(20):11461–7. doi:10.1128/JVI.02423-06.
   PubMed Web of Science ®Google Scholar
• Larsen MV, Lundegaard C, Lamberth K, Buus S, Lund O, Nielsen M. Large-scale validation of methods for cytotoxic T-lymphocyte epitope prediction. BMC Bioinform. 2007;8(1):424. doi:10.1186/1471-2105-8-424.
   PubMed Web of Science ®Google Scholar
• Reynisson B, Barra C, Kaabinejadian S, Hildebrand WH, Peters B, Nielsen M. Improved prediction of MHC II antigen presentation through integration and motif deconvolution of mass spectrometry MHC eluted ligand data. J Proteome Res. 2020;19(6):2304–15. doi:10.1021/acs.jproteome.9b00874.
   PubMed Web of Science ®Google Scholar
• Doytchinova IA, Flower DR. VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines. BMC Bioinform. 2007;8(1):4. doi:10.1186/1471-2105-8-4.
   PubMed Web of Science ®Google Scholar
• Dimitrov I, Bangov I, Flower DR, Doytchinova I. AllerTOP v.2—a server for in silico prediction of allergens. J Mol Model. 2014;20(6):2278. doi:10.1007/s00894-014-2278-5.
   PubMed Web of Science ®Google Scholar
• Gupta S, Kapoor P, Chaudhary K, Gautam A, Kumar R, Raghava GPS, Open Source Drug Discovery C. In silico approach for predicting toxicity of peptides and proteins. PLoS One. 2013;8(9):e73957. doi:10.1371/journal.pone.0073957.
   PubMed Web of Science ®Google Scholar
• Dhanda SK, Gupta S, Vir P, Raghava GP. Prediction of IL4 inducing peptides. Clin Dev Immunol. 2013;2013:1–9. doi:10.1155/2013/263952.
   Google Scholar
• Dhanda SK, Vir P, Raghava GP. Designing of interferon-gamma inducing MHC class-II binders. Biol Direct. 2013;8(1):30. doi:10.1186/1745-6150-8-30.
   PubMed Web of Science ®Google Scholar
• Saha S, Raghava GP. Prediction of continuous B-cell epitopes in an antigen using recurrent neural network. Proteins. 2006;65(1):40–8. doi:10.1002/prot.21078.
   PubMed Web of Science ®Google Scholar
• Chen C, Li Z, Huang H, Suzek BE, Wu CH, UniProt C. A fast peptide match service for UniProt knowledgebase. Bioinformatics. 2013;29(21):2808–9. doi:10.1093/bioinformatics/btt484.
   PubMed Web of Science ®Google Scholar
• Baek M, DiMaio F, Anishchenko I, Dauparas J, Ovchinnikov S, Lee GR, Wang J, Cong Q, Kinch LN, Schaeffer RD, et al. Accurate prediction of protein structures and interactions using a three-track neural network. Science. 2021;373(6557):871–6. doi:10.1126/science.abj8754.
   PubMed Web of Science ®Google Scholar
• Narang PK, Dey J, Mahapatra SR, Ghosh M, Misra N, Suar M, Kumar V, Raina V. Functional annotation and sequence-structure characterization of a hypothetical protein putatively involved in carotenoid biosynthesis in microalgae. S Afr J Bot. 2021;141:219–26. doi:10.1016/j.sajb.2021.04.014.
   Web of Science ®Google Scholar
• Wiederstein M, Sippl MJ. ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic Acids Res. 2007;35(Web Server):W407–10. doi:10.1093/nar/gkm290.
   PubMed Web of Science ®Google Scholar
• van Zundert GCP, Rodrigues J, Trellet M, Schmitz C, Kastritis PL, Karaca E, Melquiond ASJ, van Dijk M, de Vries SJ, Bonvin AMJJ. The HADDOCK2.2 web server: user-friendly integrative modeling of biomolecular complexes. J Mol Biol. 2016;428(4):720–5. doi:10.1016/j.jmb.2015.09.014.
   PubMed Web of Science ®Google Scholar
• Kutzner C, Kniep C, Cherian A, Nordstrom L, Grubmuller H, de Groot BL, Gapsys V. GROMACS in the cloud: a global supercomputer to speed up alchemical drug design. J Chem Inf Model. 2022;62(7):1691–711. doi:10.1021/acs.jcim.2c00044.
   PubMed Web of Science ®Google Scholar
• Rapin N, Lund O, Castiglione F. Immune system simulation online. Bioinformatics. 2011;27(14):2013–4. doi:10.1093/bioinformatics/btr335.
   PubMed Web of Science ®Google Scholar
• Rapin N, Lund O, Bernaschi M, Castiglione F, Brusic V. Computational immunology meets bioinformatics: the use of prediction tools for molecular binding in the simulation of the immune system. PLoS One. 2010;5(4):e9862. doi:10.1371/journal.pone.0009862.
   PubMed Web of Science ®Google Scholar
• Kim SC, Sekhon SS, Shin WR, Ahn G, Cho BK, Ahn JY, Kim Y-H. Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency. Mol Cell Toxicol. 2022;18(1):1–8. doi:10.1007/s13273-021-00171-4.
   PubMed Web of Science ®Google Scholar
• Kou Y, Xu Y, Zhao Z, Liu J, Wu Y, You Q, Wang L, Gao F, Cai L, Jiang C, et al. Tissue plasminogen activator (tPA) signal sequence enhances immunogenicity of MVA-based vaccine against tuberculosis. Immunol Lett. 2017;190:51–7. doi:10.1016/j.imlet.2017.07.007.
   PubMed Web of Science ®Google Scholar
• Kreiter S, Selmi A, Diken M, Sebastian M, Osterloh P, Schild H, Huber C, Türeci O, Sahin U. Increased antigen presentation efficiency by coupling antigens to MHC class I trafficking signals. J Immunol. 2008;180(1):309–18. doi:10.4049/jimmunol.180.1.309.
   PubMed Web of Science ®Google Scholar
• Rcheulishvili N, Mao J, Papukashvili D, Liu C, Wang Z, Zhao J, Xie F, Pan X, Ji Y, He Y, et al. Designing multi-epitope mRNA construct as a universal influenza vaccine candidate for future epidemic/pandemic preparedness. Int J Biol Macromol. 2023;226:885–99. doi:10.1016/j.ijbiomac.2022.12.066.
   PubMed Web of Science ®Google Scholar
• Rybakova Y, Kowalski PS, Huang Y, Gonzalez JT, Heartlein MW, DeRosa F, Delcassian D, Anderson DG. mRNA delivery for therapeutic anti-HER2 antibody expression in vivo. Mol Ther. 2019;27(8):1415–23. doi:10.1016/j.ymthe.2019.05.012.
   PubMed Web of Science ®Google Scholar
• Grote A, Hiller K, Scheer M, Munch R, Nortemann B, Hempel DC, Jahn D. JCat: a novel tool to adapt codon usage of a target gene to its potential expression host. Nucleic Acids Res. 2005;33:W526–31. doi:10.1093/nar/gki376.
   PubMed Web of Science ®Google Scholar
• Cseke G, Wright DW, Tollefson SJ, Johnson JE, Crowe JE Jr., Williams JV. Human metapneumovirus fusion protein vaccines that are immunogenic and protective in cotton rats. J Virol. 2007;81(2):698–707. doi:10.1128/JVI.00844-06.
   PubMed Web of Science ®Google Scholar
• Ogonczyk Makowska D, Hamelin ME, Boivin G. Engineering of live chimeric vaccines against human metapneumovirus. Pathogens. 2020;9(2):135. doi:10.3390/pathogens9020135.
   PubMed Web of Science ®Google Scholar
• Cox RG, Erickson JJ, Hastings AK, Becker JC, Johnson M, Craven RE, Tollefson SJ, Boyd KL, Williams JV, et al. Human metapneumovirus virus-like particles induce protective B and T cell responses in a mouse model. J Virol. 2014;88(11):6368–79. doi:10.1128/JVI.00332-14.
   PubMed Web of Science ®Google Scholar
• Levy C, Aerts L, Hamelin ME, Granier C, Szecsi J, Lavillette D, Boivin G, Cosset F-L. Virus-like particle vaccine induces cross-protection against human metapneumovirus infections in mice. Vaccine. 2013;31(25):2778–85. doi:10.1016/j.vaccine.2013.03.051.
   PubMed Web of Science ®Google Scholar
• Shaw CL, Smolenov S, Panther T, Kalidindi I, Zaks L, Smolenov I, Panther L. 2754. Phase 1 trial of an mRNA-based combination vaccine against hMPV and PIV3. Open Forum Infect. 2019;6(Supplement_2):S970. doi:10.1093/ofid/ofz360.2431.
   Google Scholar
• Karron RA, San Mateo J, Wanionek K, Collins PL, Buchholz UJ. Evaluation of a live attenuated human metapneumovirus vaccine in adults and children. J Pediatric Infect Dis Soc. 2018;7(1):86–9. doi:10.1093/jpids/pix006.
   PubMed Web of Science ®Google Scholar
• Biacchesi S, Pham QN, Skiadopoulos MH, Murphy BR, Collins PL, Buchholz UJ. Infection of nonhuman primates with recombinant human metapneumovirus lacking the SH, G, or M2-2 protein categorizes each as a nonessential accessory protein and identifies vaccine candidates. J Virol. 2005;79(19):12608–13. doi:10.1128/JVI.79.19.12608-12613.2005.
   PubMed Web of Science ®Google Scholar
• Buchholz UJ, Biacchesi S, Pham QN, Tran KC, Yang L, Luongo CL, Skiadopoulos MH, Murphy BR, Collins PL. Deletion of M2 gene open reading frames 1 and 2 of human metapneumovirus: effects on RNA synthesis, attenuation, and immunogenicity. J Virol. 2005;79(11):6588–97. doi:10.1128/JVI.79.11.6588-6597.2005.
   PubMed Web of Science ®Google Scholar
• August A, Shaw CA, Lee H, Knightly C, Kalidindia S, Chu L, Essink BJ, Seger W, Zaks T, Smolenov I, et al. Safety and immunogenicity of an mRNA-based human metapneumovirus and parainfluenza virus type 3 combined vaccine in healthy adults. Open Forum Infect Dis. 2022;9(7):ofac206. doi:10.1093/ofid/ofac206.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Liang S, Zhang S, Zhang S, Yu Y, Yao H, Liu Y, Zhang W, Liu G. Development and evaluation of a multi-epitope subunit vaccine against group B Streptococcus infection. Emerg Microbes Infect. 2022;11(1):2371–82. doi:10.1080/22221751.2022.2122585.
   PubMed Web of Science ®Google Scholar
• Leon Y, Zapata L, Molina RE, Okanovic G, Gomez LA, Daza-Castro C, Flores-Concha M, Reyes JL, Oñate AA. Intranasal immunization of mice with multiepitope chimeric vaccine candidate based on conserved autotransporters SigA, Pic and Sap, confers protection against shigella flexneri. Vaccines (Basel). 2020;8(4):563. doi:10.3390/vaccines8040563.
   PubMed Web of Science ®Google Scholar
• Van Den Bergh A, Bailly B, Guillon P, von Itzstein M, Dirr L. Antiviral strategies against human metapneumovirus: targeting the fusion protein. Antiviral Res. 2022;207:105405. doi:10.1016/j.antiviral.2022.105405.
   PubMed Web of Science ®Google Scholar
• Guo L, Li L, Liu L, Zhang T, Sun M. Neutralising antibodies against human metapneumovirus. Lancet Microbe. 2023;4(9):e732–e44. doi:10.1016/S2666-5247(23)00134-9.
   PubMedGoogle Scholar
• Stepanova E, Matyushenko V, Rudenko L, Isakova-Sivak I. Prospects of and barriers to the development of epitope-based vaccines against human metapneumovirus. Pathogens. 2020;9(6):481. doi:10.3390/pathogens9060481.
   PubMed Web of Science ®Google Scholar
• Ryder AB, Tollefson SJ, Podsiad AB, Johnson JE, Williams JV. Soluble recombinant human metapneumovirus G protein is immunogenic but not protective. Vaccine. 2010;28(25):4145–52. doi:10.1016/j.vaccine.2010.04.007.
   PubMed Web of Science ®Google Scholar
• Bao X, Kolli D, Liu T, Shan Y, Garofalo RP, Casola A. Human metapneumovirus small hydrophobic protein inhibits NF-κB transcriptional activity. J Virol. 2008;82(16):8224–9. doi:10.1128/JVI.02584-07.
   PubMed Web of Science ®Google Scholar
• Bao X, Liu T, Shan Y, Li K, Garofalo RP, Casola A, Baric RS. Human metapneumovirus glycoprotein G inhibits innate immune responses. PLoS Pathog. 2008;4(5):e1000077. doi:10.1371/journal.ppat.1000077.
   PubMed Web of Science ®Google Scholar
• Skiadopoulos MH, Biacchesi S, Buchholz UJ, Amaro-Carambot E, Surman SR, Collins PL, Murphy BR. Individual contributions of the human metapneumovirus F, G, and SH surface glycoproteins to the induction of neutralizing antibodies and protective immunity. Virology. 2006;345(2):492–501. doi:10.1016/j.virol.2005.10.016.
   PubMed Web of Science ®Google Scholar
• Ren J, Wang Q, Kolli D, Prusak DJ, Tseng CT, Chen ZJ, Li K, Wood TG, Bao X. Human metapneumovirus M2-2 protein inhibits innate cellular signaling by targeting MAVS. J Virol. 2012;86(23):13049–61. doi:10.1128/JVI.01248-12.
   PubMed Web of Science ®Google Scholar
• Schowalter RM, Smith SE, Dutch RE. Characterization of human metapneumovirus F protein-promoted membrane fusion: critical roles for proteolytic processing and low pH. J Virol. 2006;80(22):10931–41. doi:10.1128/JVI.01287-06.
   PubMed Web of Science ®Google Scholar
• Dey J, Mahapatra SR, Singh P, Patro S, Kushwaha GS, Misra N, Suar M. B and T cell epitope-based peptides predicted from clumping factor protein of staphylococcus aureus as vaccine targets. Microb Pathog. 2021;160:105171. doi:10.1016/j.micpath.2021.105171.
   PubMed Web of Science ®Google Scholar
• Li G, Huang Z, Zhang C, Dong BJ, Guo RH, Yue HW, Yan L-T, Xing X-H. Construction of a linker library with widely controllable flexibility for fusion protein design. Appl Microbiol Biotechnol. 2016;100(1):215–25. doi:10.1007/s00253-015-6985-3.
   PubMed Web of Science ®Google Scholar
• Ashhurst AS, Johansen MD, Maxwell JWC, Stockdale S, Ashley CL, Aggarwal A, Siddiquee R, Miemczyk S, Nguyen DH, Mackay JP, et al. Mucosal TLR2-activating protein-based vaccination induces potent pulmonary immunity and protection against SARS-CoV-2 in mice. Nat Commun. 2022;13(1):6972. doi:10.1038/s41467-022-34297-3.
   PubMed Web of Science ®Google Scholar
• Gu Y, Yang J, He C, Zhao T, Lu R, Liu J, Mo X, Wen F, Shi H. Incorporation of a Toll-like receptor 2/6 agonist potentiates mRNA vaccines against cancer and infectious diseases. Sig Transduct Target Ther. 2023;8(1):273. doi:10.1038/s41392-023-01479-4.
   PubMed Web of Science ®Google Scholar
• Kim J, Yang YL, Jang SH, Jang YS. Human β-defensin 2 plays a regulatory role in innate antiviral immunity and is capable of potentiating the induction of antigen-specific immunity. Virol J. 2018;15(1):124. doi:10.1186/s12985-018-1035-2.
   PubMed Web of Science ®Google Scholar
• Mei HF, Jin XB, Zhu JY, Zeng AH, Wu Q, Lu XM, Li X-B, Shen J. β-defensin 2 as an adjuvant promotes anti-melanoma immune responses and inhibits the growth of implanted murine melanoma in vivo. PLoS One. 2012;7(2):e31328. doi:10.1371/journal.pone.0031328.
   PubMed Web of Science ®Google Scholar
• Dey J, Mahapatra SR, Lata S, Patro S, Misra N, Suar M. Exploring Klebsiella pneumoniae capsule polysaccharide proteins to design multiepitope subunit vaccine to fight against pneumonia. Expert Rev Vaccines. 2022;21(4):569–87. doi:10.1080/14760584.2022.2021882.
   PubMed Web of Science ®Google Scholar
• Wilkins MR, Gasteiger E, Bairoch A, Sanchez JC, Williams KL, Appel RD. Protein identification and analysis tools in the ExPASy server. Methods Mol Biol. 1999;112:531–52.
   PubMedGoogle Scholar
• Funchal GA, Jaeger N, Czepielewski RS, Machado MS, Muraro SP, Stein RT, Bonorino CBC, Porto BN. Respiratory syncytial virus fusion protein promotes TLR-4–dependent neutrophil extracellular trap formation by human neutrophils. PLoS One. 2015;10(4):e0124082. doi:10.1371/journal.pone.0124082.
   PubMed Web of Science ®Google Scholar
• Kurt-Jones EA, Popova L, Kwinn L, Haynes LM, Jones LP, Tripp RA, Walsh EE, Freeman MW, Golenbock DT, Anderson LJ, et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol. 2000;1(5):398–401. doi:10.1038/80833.
   PubMed Web of Science ®Google Scholar
• Rassa JC, Meyers JL, Zhang Y, Kudaravalli R, Ross SR. Murine retroviruses activate B cells via interaction with toll-like receptor 4. Proc Natl Acad Sci USA. 2002;99(4):2281–6. doi:10.1073/pnas.042355399.
   PubMed Web of Science ®Google Scholar
• Murawski MR, Bowen GN, Cerny AM, Anderson LJ, Haynes LM, Tripp RA, Kurt-Jones EA, Finberg RW. Respiratory syncytial virus activates innate immunity through Toll-like receptor 2. J Virol. 2009;83(3):1492–500. doi:10.1128/JVI.00671-08.
   PubMed Web of Science ®Google Scholar
• Alshaghdali K, Saeed M, Kamal MA, Saeed A. Interaction of ectodomain of respiratory syncytial virus G protein with TLR2/TLR6 heterodimer: an in vitro and in silico approach to decipher the role of RSV G protein in pro-inflammatory response against the virus. Curr Pharm Des. 2021;27(44):4464–76. doi:10.2174/1381612827666210716160030.
   PubMed Web of Science ®Google Scholar